Patent · US Active

α4α7 peptide monomer and dimer antagonists

US11111272B2 · kind B2 · utility

8Cited by

35References

14Claims

0Family size

Assignee

Protagonist Therapeutics, Inc. · US

Inventors

Ashok Bhandari · Pleasanton, US
Dinesh V. Patel · Fremont, US
Genet Zemede · San Jose, US
Larry C. Mattheakis · Cupertino, US
David Liu · Palo Alto, US

Key dates

Filing date	Feb 4, 2020
Grant date	Sep 7, 2021
Priority date	—
Expiry date	Feb 4, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.